Amer Zeidan, MBBS, of Yale Cancer Center, discussed the COMMANDS trial of frontline luspatercept in transfusion-dependent patients with lower-risk MDS and anemia at the 66th American Society of Hematology Annual Meeting & Exposition.
Advertisement
Advertisement
The CRL is related to observations of a third-party manufacturing facility as part of a standard prelicense inspection.
The first-of-its-type anti-CSF-1R antibody is approved for use in adult and pediatric patients who weigh at least 40 kg.
Acalabrutinib was previously granted priority review in October 2024 based on results from the phase 3 ECHO trial.
Patient-reported outcomes of the CARTITUDE-4 trial showed an improvement in quality of life with cilta-cel versus SOC.
Extended follow-up was conducted for 652 patients with relapsed or refractory CLL or SLL in the ALPINE study.
Advertisement
Podcasts
Dr. Usmani, of the Memorial Sloan Kettering Cancer Center, highlights multiple myeloma news from the SOHO 2024 conference.
Dr. Venugopal, of the Sylvester Comprehensive Cancer Center, shares MDS updates from the SOHO 2024 meeting.
Dr. Daver highlights AML news from the Twelfth Annual Meeting of the Society of Hematologic Oncology.
Dr. Shadman, of the Fred Hutchinson Cancer Center, shares CLL news from the SOHO 2024 Annual Meeting.
Dr. Bose highlights news on MPN featured at the SOHO 2024 Annual Meeting.
Dr. Osman discusses classification and treatment approaches for patients with high-risk MDS.
Rami Komrokji, MD, describes incorporation of molecular data, tailoring treatment by disease risk, and new therapies in MDS.
Dr. Hilal covers the debates surrounding MRD, whether he uses MRD to make treatment decisions, and more.
Video Insights
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Knowledge Hubs
Trending on MashupMD
Nature
Extended Look Into Long-Term Zoledronic Acid in Multiple Myeloma
ManniMD1
ManniMD1Manni Mohyuddin, MD, covers new data suggesting that
#myeloma #mmsm
American Society of Hematology
Two NK Receptor Ligands Control T-cell Targeting of AML Cells
BloodJournal
BloodJournalStudy finds two NK receptor ligands, PVR and B7-H6,
#immunobiologyandimmunotherapy
#myeloidneoplasia
FDA
FDA approves bosutinib for pediatric patients with chronic myelogenous leukemia
NatureRevClinOncol
NatureRevClinOncolYesterday, the FDA approved the BCR-ABL1 inhibitor b
#FDA
#CML
The Lancet Haematology
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the
The Lancet Haematology
The Lancet Haematology NEW online: results from the ph2 MASTER trial sugges
#mmsm
American Society of Clinical Oncology
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.